Takeda Pharmaceutical Company Limited announced that its Board of Directors unanimously decided to appoint Julie Kim as the successor to Christophe Weber, the current president, chief executive officer, and representative director. Mr. Weber will retire from the company in June 2026.
Julie Kim currently serves as the president of Takeda’s U.S. Business Unit. She will be proposed as a candidate for election to the Board at Takeda’s Annual General Shareholders Meeting.
This planned leadership transition ensures continuity and strategic alignment for Takeda. The appointment of an internal candidate like Ms. Kim reflects a commitment to leveraging existing talent and maintaining the company's strategic vision.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.